TEL-AVIV, Israel, July 14, 2015 /PRNewswire/ --
Elbit Imaging Ltd. (TASE, NASDAQ: EMITF) ("Elbit" or the
"Company") announced today following the Company's announcements
dated October 5, 2014 and
April 15, 2015 that it was
informed by InSightec Ltd. ("InSightec"), that Blue Cross Blue
Shield of Massachusetts, Blue
Cross Blue Shield of Mississippi,
Wellmark Blue Cross Blue Shield, Blue Cross of Idaho and Blue Cross Blue Shield of
Arizona have published updates to
their Magnetic Resonance Imaging-guided Focused Ultrasound (MRgFUS)
coverage policy and are now providing benefits for INSIGHTEC's
ExAblate® procedure as a treatment option that is FDA-approved for
patients suffering from pain associated with bone metastases.
InSightec estimates that such favorable policy update will make
available to the members of Blue Cross Blue Shield of Massachusetts, Blue Cross Blue Shield of
Mississippi, Wellmark Blue Cross
Blue Shield, Blue Cross of Idaho
and Blue Cross Blue Shield of Arizona, treatments for painful bone
metastases using InSightec's ExAblate® procedure as a treatment
option cleared by the Food and Drug Administration (FDA).
Blue Cross Blue Shield of Massachusetts, Blue Cross Blue Shield of
Mississippi, Wellmark Blue Cross
Blue Shield, Blue Cross of Idaho
and Blue Cross Blue Shield of Arizona provide benefits to about 6.2 million
members combined.
The Company holds approximately 82.7% of the share capital of
Elbit Medical Technologies Ltd. ("Elbit Medical") (TASE:
EMTC-M) (on a fully diluted basis) which, in turn, holds
approximately 29.6% of the share capital in InSightec (on a fully
diluted basis).
About Elbit Imaging Ltd.
Elbit Imaging Ltd. operates in the following principal fields of
business: (i) Commercial centers - initiation, construction, and
sale of commercial centers and other mixed-use property projects,
predominantly in the retail sector, located in Central and
Eastern Europe and in India. In certain circumstances and depending
on market conditions, the Group operates and manages commercial
centers prior to their sale. (ii) Hotels - hotels operation and
management. (iii) Medical industries and devices - (a) research and
development, production and marketing of magnetic resonance imaging
guided focused ultrasound treatment equipment, and (b) development
of stem cell population expansion technologies and stem cell
therapy products for transplantation and regenerative medicine.
(iv) Residential projects - initiation, construction and sale of
residential units or plots designated for residential located
primarily in India.
Safe Harbor Statement under the Private Securities Litigation
Reform Act of 1995
Any forward-looking statements in our releases include
statements regarding the intent, belief or current expectations of
Elbit Imaging Ltd. and our management about our business, financial
condition, results of operations, and its relationship with its
employees and the condition of our properties. Words such as
"believe," "would,"
"expect," "intend,"
"estimate" and similar expressions are
intended to identify forward-looking statements but are not the
exclusive means of identifying such statements. Actual results may
differ materially from those projected, expressed or implied in the
forward-looking statements as a result of various factors
including, without limitation, the factors set forth
in our filings with the Securities and Exchange Commission
including, without limitation, Item 3.D of our annual report on
Form 20-F for the fiscal year ended December
31, 2014, under the caption
"Risk Factors." Any forward-looking
statements contained in our releases speak only as of the date of
such release, and we caution existing and prospective investors not
to place undue reliance on such statements. Such forward-looking
statements do not purport to be predictions of future events or
circumstances, and therefore, there can be no assurance that any
forward-looking statement contained our releases will prove to be
accurate. We undertake no obligation to update or revise any
forward-looking statements.
For Further Information:
Company Contact
Ron Hadassi
Chairman of the Board of Directors
Tel: +972-3-608-6048
Fax: +972-3-608-6050
ron@elbitimaging.com
SOURCE Elbit Imaging Ltd.